Last updated: March 2026
Nandrolone (Deca-Durabolin, NPP) is an FDA-approved injectable 19-nor steroid with a unique profile: moderate anabolic potency, documented collagen synthesis benefits, and the longest drug detection window of any commonly used AAS. Understanding its progestogenic activity is critical to harm reduction.
Nandrolone's 19-nor structure (missing the 19th carbon of testosterone) gives it a distinct pharmacological profile — moderate androgen receptor activity, unique 5α-reduction product, and significant progestogenic effects.
Nandrolone is among the few anabolic steroids with documented collagen synthesis stimulation. Studies show increased procollagen type I and III synthesis in connective tissue. This translates to improved joint lubrication, reduced pain in high-volume training, and accelerated tendon/ligament repair. Multiple clinical trials in osteoarthritis confirm this mechanistically distinct benefit.
Unlike testosterone (which converts to potent DHT via 5α-reductase), nandrolone converts to dihydronandrolone (DHN), which has very weak androgen receptor affinity. This makes nandrolone relatively "androgenic-sparing" in DHT-sensitive tissues (scalp, prostate, skin). However, DHN can competitively displace testosterone from androgen receptors in penile tissue — contributing to the "deca dick" phenomenon.
Nandrolone binds progesterone receptors with moderate affinity. This progestogenic activity suppresses dopaminergic tone in the hypothalamus — a pathway critical for libido and sexual function. Combined with HPTA suppression (no LH/FSH, no endogenous testosterone), the result is the notorious "deca dick" effect: erectile dysfunction and loss of libido. Concurrent testosterone use is the primary mitigation strategy.
Nandrolone decanoate (Deca-Durabolin) has FDA approval for anemia associated with renal insufficiency. It stimulates EPO production and erythropoiesis, raising hemoglobin and hematocrit. The clinical approved dose is 50-200mg every 1-4 weeks. Community use at higher doses (200-600mg/week) amplifies both anabolic and side-effect profiles substantially.
Clinical and anemia trial data alongside community-reported outcomes. Nandrolone has more published clinical research than most AAS.
Key monitoring supplies for nandrolone research protocols.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm-reduction purposes only. Nandrolone (Deca-Durabolin, NPP) is a Schedule III controlled substance under the Anabolic Steroid Control Act. While it has FDA approval for specific medical indications, use outside a valid prescription is illegal in the United States. This content does not constitute medical advice. Always consult a licensed physician before using any anabolic agent. WADA detection windows of 18+ months make nandrolone incompatible with participation in tested athletic competition.